SL Science Holding Ltd（SLBT）股價、財務與研究

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

2026年7月10日

22/ 100

GoAI 評分

賣出

估值

10

估值過高

情緒

50

多空交錯

風險

63

高風險

動能

17

強勢下行

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

公司概況

公司網站

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company’s products include SL bio’s milk-derived exosome essence, SL bio’s tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026. The company is based in Taipei, Taiwan.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: William Wang
上市以來: 2025年2月5日
僱員: 15

市場位置

日內區間

目前US$1.51

US$1.50US$1.61

52週區間

目前US$1.51

US$1.42US$14.50

開盤價: US$1.50
前收盤價: US$1.52
成交量: 2.59萬; 0.04× 平均值
平均成交量: 58.5萬; 日均成交量
市值: 8.47億 USD
貝塔: 0.09; 市場參考 1
50天平均值: US$2.3131; 低於平均水平-34.72%
200天平均值: US$6.7794; 低於平均水平-77.73%

財務數據

財務快照

估值與收益率

企業價值: -104.52萬 USD
本益比（TTM）: 0×
股價淨值比（TTM）: 0×
股價營收比（TTM）: 385.37×
EV/EBITDA: 0.28×
盈餘收益率: 0.00%
自由現金流收益率: 0.00%
股息率: 0.00%

獲利能力和效率

毛利率: 35.27%
營業利益率: -174.65%
淨利潤率: -173.85%
股東權益報酬率: -167.25%
資產報酬率: -135.59%
投入資本報酬率: -153.66%

財務健康

負債權益比: 0.09×
流動比率: 3.05×

財務報表

利潤率趨勢

獲利能力占已公布營收的百分比。

毛利率營業利益率淨利潤率

損益趨勢

營收

219.72萬 USD-34.68%

營業利益

−383.75萬 USD-220.83%

淨利

−381.98萬 USD-220.63%

財務報表: 損益表
項目（USD）	2025會計年度	2024會計年度	2023會計年度
營收	219.72萬 USD	336.36萬 USD	87.9萬 USD
銷貨成本	142.22萬 USD	143.08萬 USD	14.1萬 USD
毛利	77.51萬 USD	193.28萬 USD	73.8萬 USD
研究與開發	206.9萬 USD	202.03萬 USD	—
銷售、一般及管理費用	254.35萬 USD	110.85萬 USD	64.12萬 USD
營業費用	461.26萬 USD	312.89萬 USD	64.12萬 USD
利息收入	4.03萬 USD	4.53萬 USD	1612 USD
折舊和攤銷	9.37萬 USD	4.72萬 USD	3.72萬 USD
營業利益	−383.75萬 USD	−119.61萬 USD	9.68萬 USD
淨利	−381.98萬 USD	−119.13萬 USD	39.9萬 USD

公司資料更新於 2026年10月11日。

財報歷史與展望

最新財年每股收益: 0; 2025會計年度
最新財年收入: 219.72萬 USD; 2025會計年度 · 年增-34.68%

年度每股收益趨勢

已公布業績及可用的市場共識預估。

已公布市場共識預估

年度營收趨勢

已公布業績及可用的市場共識預估。

已公布市場共識預估

SLBT 訊息

globenewswire.com2026年9月24日

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

New findings highlight the therapy's ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence.

閱讀原始碼

seekingalpha.com2026年9月16日

SL Science: A $1.15 Billion Valuation Built On Preclinical Promises

SL Science Holding Limited is rated Sell due to an unsustainable $1.15B valuation built on a strictly preclinical pipeline. SLBT's flagship Gamma Delta T cell therapy targets aggressive solid tumors but has not entered…

閱讀原始碼

globenewswire.com2026年9月2日

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene…

閱讀原始碼

globenewswire.com2026年8月27日

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene…

閱讀原始碼

globenewswire.com2026年8月11日

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and…

閱讀原始碼

globenewswire.com2026年7月17日

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies.

閱讀原始碼

SLBT同業公司

AMGN

Amgen Inc.

US$414.87

+1.82%

GILD

Gilead Sciences, Inc.

US$151.17

+2.77%

ISRG

Intuitive Surgical, Inc.

US$423.96

+2.06%

VRTX

Vertex Pharmaceuticals Incorporated

US$510.08

+1.36%

SNY

Sanofi

US$40.07

-0.40%

MRNA

Moderna, Inc.

US$225

+14.21%

SL Science Holding Ltd

SLBT公司概覽

公司概況

SL Science Holding Ltd

SLBT公司概覽

GoAI 研究快照

公司概況

市場位置

財務數據

財務快照

估值與收益率

獲利能力和效率

財務健康

財務報表

利潤率趨勢

損益趨勢

財報歷史與展望

年度每股收益趨勢

年度營收趨勢

SLBT 訊息

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

SL Science: A $1.15 Billion Valuation Built On Preclinical Promises

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

SLBT同業公司

繼續GoAI的研究

SLBT公司概覽

公司概況

市場位置

SLBT公司概覽

公司概況

SLBT公司概覽

公司概況

市場位置

SLBT公司概覽

GoAI 研究快照

公司概況

市場位置

財務數據

財務快照

估值與收益率

獲利能力和效率

財務健康

財務報表

利潤率趨勢

損益趨勢

財報歷史與展望

年度每股收益趨勢

年度營收趨勢

SLBT 訊息

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

SL Science: A $1.15 Billion Valuation Built On Preclinical Promises

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

SLBT同業公司

繼續GoAI的研究